Thu, January 12, 2012
Wed, January 11, 2012
Tue, January 10, 2012
Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011

Isis Pharmaceuticals Announces Its R&D Webcast Presentation


//health-fitness.news-articles.net/content/2012/ .. cals-announces-its-r-d-webcast-presentation.html
Published in Health and Fitness on Thursday, January 5th 2012 at 7:55 GMT by Market Wire   Print publication without navigation


Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation -- CARLSBAD, Calif., Jan. 5, 2012 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation

[ ]

CARLSBAD, Calif., Jan. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]) announces the following webcast:

What:

Isis Pharmaceuticals' R&D Webcast Presentation

When:

Thursday, January 05, 2012 at 9:00 a.m. PT / 12:00 p.m. ET

Where:

[ www.isispharm.com ]

How:

Live on the Internet. Simply log on to our Web site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [ www.isispharm.com ].

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources